Description
BTRC Polyclonal Antibodyis available at Gentaur for next week delivery.
Specificity:
Alternative Names: Q9Y297
Immunogen: Recombinant Human F-box/WD repeat-containing protein 1A protein (397-448AA)
Technical Notes: For Research Use Only. Not for use in diagnostic procedures, drug use, or for administration to humans or animals.
Application: ELISA, WB, IHC, IF; Recommended dilution: WB:1:2000-1:10000, IHC:1:20-1:200, IF:1:50-1:200
Restriction:
Comments: Preservative: 0.03% Proclin 300; Constituents: 50% Glycerol, 0.01M PBS, PH 7.4; Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds to phosphorylated target proteins. SCF(BTRC) mediates the ubiquitination of CTNNB1 and participates in Wnt signaling. SCF(BTRC) mediates the ubiquitination of NFKBIA, NFKBIB and NFKBIE; the degradation frees the associated NFKB1 to translocate into the nucleus and to activate transcription. Ubiquitination of NFKBIA occurs at 'Lys-21' and 'Lys-22'. SCF(BTRC) mediates the ubiquitination of CEP68; this is required for centriole separation during mitosis (PubMed:25704143, PubMed:25503564). SCF(BTRC) mediates the ubiquitination of phosphorylated NFKB1/nuclear factor NF-kappa-B p105 subunit, ATF4, CDC25A, DLG1, FBXO5, PER1, SMAD3, SMAD4, SNAI1 and probably NFKB2. Has an essential role in the control of the clock-dependent transcription via degradation of phosphorylated PER1 and PER2. May be involved in ubiquitination and subsequent proteasomal degradation through a DBB1-CUL4 E3 ubiquitin-protein ligase. Required for activation of NFKB-mediated transcription by IL1B, MAP3K14, MAP3K1, IKBKB and TNF. Required for proteolytic processing of GLI3.
Additional Information
Species Reactivity: |
Human |
Size: |
100ug |
Host: |
Rabbit |
Clonality: |
Polyclonal |
Concentration: |
-20°C |
Storage: |
1 year |
Expiry Date: |
Ice packs |
Shipping Condition: |
Conjugation service and the corresponding secondary antibody are available. |